Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EGFRvIII-directed IL-10 CAR-T
- Development stage
- Preclinical
- Lead developer
- Leman Biotech
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
EGFRvIII-directed IL-10 CAR-T (also referred to as Meta 10C-based IL-10 CAR-T) is a preclinical-stage chimeric antigen receptor T-cell (CAR-T) therapy developed by Leman Bio. The therapy utilizes the proprietary 'Meta 10C' metabolic-armoring platform, which involves engineering CAR-T cells to express the immunomodulatory cytokine IL-10 alongside a CAR targeting the tumor-specific antigen EGFRvIII (epidermal growth factor receptor variant III). This approach is designed to overcome the immunosuppressive tumor microenvironment by enhancing the metabolic fitness, persistence, and anti-tumor activity of the T cells. Preclinical studies in the 4T1-EGFRvIII syngeneic mouse model of breast cancer demonstrated a 100% cure rate, suggesting potential efficacy against EGFRvIII-positive solid tumors.
- Other names
- Meta 10C-based IL-10 CAR-TMeta10C-based IL-10 CAR-TMeta-10C-based IL-10 CAR-TIL-10 armored EGFRvIII CAR-TIL10 armored EGFRvIII CAR-TIL 10 armored EGFRvIII CAR-TIL-10 CAR-T + 4T1-EGFRvIIIEGFRvIII-directed IL-10 CAR-T
02
Targets
IL10RA (Interleukin-10 Receptor)EGFRvIII (Epidermal growth factor receptor variant III)
Beyond the preview
Go deeper on EGFRvIII-directed IL-10 CAR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EGFRvIII-directed IL-10 CAR-T.